

Alexandre Buffet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4665926/publications.pdf>

Version: 2024-02-01

18
papers

1,887
citations

623734

14
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

2550
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying evidence toward pathogenicity for rare phenotypes: The case of succinate dehydrogenase genes, SDHB and SDHD. <i>Genetics in Medicine</i> , 2022, 24, 41-50.	2.4	5
2	Germline <i>DLST</i> Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 459-471.	3.6	6
3	Screening of a Large Cohort of Asymptomatic <i>SDHx</i> Mutation Carriers in Routine Practice. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1301-e1315.	3.6	10
4	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , 2021, 17, 435-444.	9.6	80
5	Succinate detection using in vivo 1H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1510-1517.	6.4	22
6	An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101416.	4.7	106
7	Germline mutations in the new E1 TM cryptic exon of the <i>VHL</i> gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma. <i>Journal of Medical Genetics</i> , 2020, 57, 752-759.	3.2	12
8	TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2 [±] -Driven Mesenchymal Transition. <i>Cell Reports</i> , 2020, 30, 4551-4566.e7.	6.4	49
9	Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. <i>Journal of Medical Genetics</i> , 2019, 56, 513-520.	3.2	60
10	Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1109-1118.	3.6	82
11	Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2019, 25, 760-770.	7.0	82
12	Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier <i>SLC25A11</i> Gene Confer a Predisposition to Metastatic Paragangliomas. <i>Cancer Research</i> , 2018, 78, 1914-1922.	0.9	96
13	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. <i>Genetics in Medicine</i> , 2018, 20, 1652-1662.	2.4	45
14	Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. <i>Blood</i> , 2018, 132, 469-483.	1.4	70
15	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. <i>Nature Communications</i> , 2015, 6, 6044.	12.8	153
16	Mosaicism in <i>HIF2A</i> -Related Polycythemia-Paraganglioma Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E369-E373.	3.6	87
17	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. <i>Human Molecular Genetics</i> , 2014, 23, 2440-2446.	2.9	316
18	SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. <i>Cancer Cell</i> , 2013, 23, 739-752.	16.8	606